UBS Group
CALT

UBS Group’s Calliditas Therapeutics AB American Depositary Shares CALT Stock Holding History

UBS Group’s Portfolio CALT Stock Details CALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-10,756
Closed -$419K – 10337
2024
Q2 		$419K Buy
+10,756
New +$296K ﹤0.01% 5135
2024
Q1 		– Sell
-952
Closed -$24.5K – 10229
2023
Q4 		$24.5K Buy
952
+911
+2,222% +$17.1K ﹤0.01% 6981
2023
Q3 		$749 Sell
41
-136
-77% -$2.35K ﹤0.01% 8301
2023
Q2 		$2.8K Sell
177
-129
-42% -$2.72K ﹤0.01% 7691
2023
Q1 		$7.33K Sell
306
-143
-32% -$2.86K ﹤0.01% 7814
2022
Q4 		$7.63K Buy
449
+190
+73% +$3.06K ﹤0.01% 8879
2022
Q3 		$4K Sell
259
-377
-59% -$6.57K ﹤0.01% 9430
2022
Q2 		$11K Sell
636
-854
-57% -$14.9K ﹤0.01% 7869
2022
Q1 		$29K Buy
1,490
+33
+2% +$662 ﹤0.01% 7043
2021
Q4 		$36K Buy
1,457
+1,295
+799% +$26K ﹤0.01% 7214
2021
Q3 		$4K Buy
162
+151
+1,373% +$4.14K ﹤0.01% 8705
2021
Q2 		$0 Sell
11
-680
-98% -$19.5K ﹤0.01% 9941
2021
Q1 		$19K Buy
+691
New +$20.6K ﹤0.01% 7448
2020
Q4 		– Sell
-836
Closed -$20K – 8861
2020
Q3 		$20K Buy
+836
New +$19.5K ﹤0.01% 6318

Other funds holding CALT

CGH
Crossmark Global Holdings Houston, Texas $7.71B AUM 37.66% 1-Year Est. Return
AP
Advisors Preferred Rockville, Maryland $679M AUM 22.19% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return
MTIC
Missouri Trust & Investment Company Springfield, Missouri $341M AUM 17.31% 1-Year Est. Return

UBS Group's CALT Position: Q3 2024 in Review

UBS Group sold out of Calliditas Therapeutics AB American Depositary Shares (CALT) in Q3 2024, closing a stake of 10,756 shares — an estimated $419K sold.

UBS Group first reported a position in CALT in Q3 2020 and held it in 14 quarters. The position peaked at $419K in Q2 2024. 5 funds tracked by Wall St. Rank hold CALT as of Q3 2024.

  • UBS Group reported no remaining Calliditas Therapeutics AB American Depositary Shares position as of Q3 2024 after selling out during the quarter.
  • UBS Group sold 10,756 Calliditas Therapeutics AB American Depositary Shares shares in Q3 2024, an estimated $419K.
  • UBS Group first reported a position in Calliditas Therapeutics AB American Depositary Shares in Q3 2020 and held it in 14 quarters.
  • UBS Group's Calliditas Therapeutics AB American Depositary Shares position peaked at $419K in Q2 2024.
  • 5 funds tracked by Wall St. Rank held Calliditas Therapeutics AB American Depositary Shares as of Q3 2024.

Based on UBS Group's 13F filing for Q3 2024, filed 14 Nov 2024.